The Recommended National Standard Led by Yunhai Bio Approved for Project Initiation —— Strengthening the Foundation of Biochemical Testing Standards and Promoting the Standardization and Industrialization of Cutting-edge Technologies

On August 15, the 11th meeting of the 3rd National Technical Committee on Biochemical Testing Standardization (SAC/TC387) was held at Shanghai Jiao Tong University. Chengdu Yunhai Tetrahedral Framework Biotechnology Co., Ltd. participated as a co-organizer, fully demonstrating its strength and commitment in the standardization of biochemical testing and frontier biotechnology.

At the opening session, Academician Chunhai Fan, Executive Dean of the Institute of Translational Medicine, emphasized that standardization in the field of bionanotechnology has become an important track in global scientific and technological competition. He noted that international organizations, including ISO and IEC, are accelerating the development of standards in emerging directions. Facing a critical period for China’s innovation-driven development, he called on the scientific community to join forces with metrology institutions, hospitals, and enterprises to better integrate frontier technologies with the standardization system of biochemical testing—advancing innovation through standards and promoting industrialization through regulations.

During the meeting, the recommended national standard “Synthesis Method for Tetrahedral DNA Nanostructure Assemblies (One-Pot Method)”, led and drafted by Yunhai Bio, was officially approved for project initiation. This milestone marks a key step forward in the construction of the standard system for this technological field. It is expected to provide reproducible workflows, verifiable key indicators, and comparable results for the preparation of tetrahedral DNA nanostructures—reducing inter-experimental variability, enhancing overall industry quality and efficiency, and offering a unified “operating manual” for research translation and industrialization.

Yunhai Bio believes that, toward practical applications, the establishment of this standard will further drive the coordinated upgrading of upstream and downstream reagents, instruments, and quality control materials, thereby accelerating the transition of frontier achievements into clinical testing, early disease screening, and drug efficacy evaluation. Moving forward, Yunhai Bio will continue to participate deeply in the development and validation of standards, working alongside universities, hospitals, and metrology institutions to optimize methodologies and promote demonstrations. At the same time, the company will actively align with domestic and international standard systems, cultivate interdisciplinary standardization talent, and strengthen the industrial ecosystem.

At this critical juncture of technological breakthroughs and accelerated industrialization, Yunhai Bio is committed to consolidating the “standard foundation” of biochemical testing with higher benchmarks and faster pace—guiding innovation with regulations, empowering industries with standards, and driving China’s bionanotechnology and biochemical testing sectors toward high-quality development at a higher level.